Insight Molecular Diagnostics expects about $0.25M Q2 2026 revenue while projecting second-quarter cash burn above $9M
Insight Molecular Diagnostics Inc. Common Stock · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · Now $6.16
-13% in 3d after detection
Post-detection moves
1h
—
1d
-0.2%
3d
-13%
7d
+0.3%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS